LONDON, June 21 (Reuters) - Shire Plc said on Thursday the U.S. Food and Drug Administration (FDA) intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit ...

A federal judge on Tuesday certified a class of drug distributors and other companies who say they paid inflated prices for Shire PLC's ADHD drug Intuniv due to an improper patent lawsuit settlement ...

Attention deficit hyperactivity disorder, or ADHD, is a common neurodevelopmental disorder that can affect children and adults. It’s often diagnosed during childhood or adolescence — in fact, an ...